Company intelligence / Profile preview

Allevo

Rotterdam, South Holland, Netherlands

Ownership: Private
Development stage: Other

Overview

Allero Therapeutics is a biotechnology company focused on developing next-generation immunotherapies for immune-mediated disorders, including autoimmune diseases and allergies. The company utilizes its proprietary SOMIT (Specific OroMucosal ImmunoTherapy) platform technology, which is designed to induce long-lasting, antigen-specific immune tolerance through non-invasive administration. Its lead programs target conditions such as celiac disease and food allergies, aiming to restore immune balance without global immunosuppression. Founded by experts in the European biotech sector, Allero was acquired by Laboratorios LETI in 2022 to further advance its pipeline of patient-friendly therapeutic solutions.

Therapeutic areas: ImmunologyGastroenterology
Modalities: ImmunotherapyPeptides
Industry: Biotech

Beyond the preview

Go deeper on Allevo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allevo.

Explore the full profile